Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial

BACKGROUND: More clinical practice need to be performed to verify the toxicity of the hypofractionated radiotherapy (HFRT) combined with PD-1 blockade in lung cancer. This phase I study aimed to investigate the safety and efficacy of nivolumab combined with HFRT in patients with progressive advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Hua, Pang, Haowen, Shi, Xiangxiang, Ren, Peirong, Huang, Shangke, Yu, Hong, Wu, Jingbo, Lin, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100893/
https://www.ncbi.nlm.nih.gov/pubmed/33968760
http://dx.doi.org/10.3389/fonc.2021.657024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100893/
https://www.ncbi.nlm.nih.gov/pubmed/33968760
http://dx.doi.org/10.3389/fonc.2021.657024

Ejemplares similares